Cadrenal Therapeutics, Inc. Common Stock (NASDAQ:CVKD) — Market Cap & Net Worth
Market Cap & Net Worth: Cadrenal Therapeutics, Inc. Common Stock (CVKD)
Cadrenal Therapeutics, Inc. Common Stock (NASDAQ:CVKD) has a market capitalization of $12.93 Million ($12.93 Million) as of August 7, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #26375 globally and #5443 in its home market, demonstrating a 14.97% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Cadrenal Therapeutics, Inc. Common Stock's stock price $5.53 by its total outstanding shares 2338127 (2.34 Million). See Cadrenal Therapeutics, Inc. Common Stock capex to cash flow ratio to understand how much of operating cash flow is reinvested back into capital assets.
Cadrenal Therapeutics, Inc. Common Stock Market Cap History: 2023 to 2026
Cadrenal Therapeutics, Inc. Common Stock's market capitalization history from 2023 to 2026. Data shows growth from $25.95 Million to $4.58 Million (1141.56% CAGR).
Index Memberships
Cadrenal Therapeutics, Inc. Common Stock is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.48 Trillion | 0.00% | #746 of 976 |
|
NASDAQ Composite
IXIC
|
$40.85 Trillion | 0.00% | #2440 of 3165 |
Weight: Cadrenal Therapeutics, Inc. Common Stock's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Cadrenal Therapeutics, Inc. Common Stock Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Cadrenal Therapeutics, Inc. Common Stock's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of CVKD by Market Capitalization
Companies near Cadrenal Therapeutics, Inc. Common Stock in the global market cap rankings as of August 7, 2026.
Key companies related to Cadrenal Therapeutics, Inc. Common Stock by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #426 globally with a market cap of $64.60 Billion USD.
- Argen-X (BR:ARGX): Ranked #546 globally with a market cap of $49.55 Billion USD ( €42.38 Billion EUR).
- UCB SA (BR:UCB): Ranked #570 globally with a market cap of $47.34 Billion USD ( €40.49 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $484.83 |
| #426 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $64.60 Billion | $768.58 |
| #546 | Argen-X | BR:ARGX | $49.55 Billion | €748.60 |
| #570 | UCB SA | BR:UCB | $47.34 Billion | €229.20 |
Cadrenal Therapeutics, Inc. Common Stock Historical Marketcap From 2023 to 2026
Between 2023 and today, Cadrenal Therapeutics, Inc. Common Stock's market cap moved from $25.95 Million to $ 4.58 Million, with a yearly change of 1141.56%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $4.58 Million | -71.09% |
| 2025 | $15.85 Million | -53.21% |
| 2024 | $33.88 Million | +30.54% |
| 2023 | $25.95 Million | -- |
End of Day Market Cap According to Different Sources
On Apr 24th, 2026 the market cap of Cadrenal Therapeutics, Inc. Common Stock was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $12.93 Million USD |
| MoneyControl | $12.93 Million USD |
| MarketWatch | $12.93 Million USD |
| marketcap.company | $12.93 Million USD |
| Reuters | $12.93 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Cadrenal Therapeutics, Inc. Common Stock
Cadrenal Therapeutics, Inc. operates as a late-stage biopharmaceutical company focuses on developing therapeutics for rare cardiovascular conditions. The company is developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with… Read more